List view / Grid view

Professor Matthew DeLisa

 

article

Advancing vaccines with extracellular vesicles

Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles…

27 September 2022 | By

Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…